Selling a Physical Therapy Practice in 2026: Multiples, Named Buyers, and the KPI Playbook

If you own a US outpatient physical therapy practice, the headline range (3x-16x EBITDA) hides what actually sets your number: the operational KPIs and the payer mix. Two practices with the same $1.5M of EBITDA can sell for $7.5M and $16.5M – same business size, $9M difference in enterprise value – and the difference is entirely about whether your productivity is 1.4 or 2.0 visits per PT per hour, whether your Medicare exposure is 70% or 30%, whether your top referral source is 35% or 12% of revenue, and whether you have retention agreements on your key clinicians. The PT consolidator landscape concentrated through 2024 (zero new platform buyouts) and resumed tuck-in activity in 2025 (ATI take-private, Access PT acquisitions, others). The buyer pool is 5-7 well-capitalized national platforms plus regional consolidators – well-funded, disciplined, and selective. This guide gives you the real multiples by practice profile (with charts), the named consolidators and what each one buys, the KPI playbook aggregators actually price, a preparation sequence in priority order, the dangers and traps that kill deals, and our view on where the market is going.

We are CT Acquisitions, a buy-side M&A advisory firm with buyers in our network actively acquiring physical therapy practices. Sellers pay nothing, the buyer pays our fee at closing. For adjacent verticals, see our guides on selling a behavioral health practice, selling an ABA therapy business, and selling a home health agency.

What a physical therapy practice is actually worth in 2026

The headline range for a US outpatient physical therapy practice is 3x to 16x EBITDA, depending almost entirely on size and operational quality. Small clinic? You’re trading at 3-6x. Mid-size regional? 5-9x. A real platform with $5M+ EBITDA, a diversified payer mix, and a proper management layer? 10-13x. The premium platform deals reach into the mid-teens (MOTION PT’s 2023 sale to Confluent Health was reported at ~12.5x). According to WebPT industry data, the 5-year average EBITDA multiple for small PT practices is roughly 3.6x, so most owners overestimate where they sit in the range.

The structural read on the PT M&A market right now

One important context: zero new platform buyouts were announced in 2024. The PE consolidators (Upstream, Athletico, Confluent, Ivy, ATI) spent the last 18 months digesting prior acquisitions and managing through reimbursement headwinds, not buying new platforms. That changed in 2025, with ATI’s take-private and an uptick in tuck-in activity from Access PT (Confluent-affiliated) and others. The big platforms are back to doing add-ons, not greenfield platform formation, which means the buyer pool right now is the 5-7 named consolidators below plus regional roll-ups, not a dozen new entrants chasing the same asset.

The buyers acquiring PT practices in 2026, by name

The operator-knowledge layer: what aggregators actually diligence in a PT practice

PT diligence is metric-heavy, and the platforms have models that price specific KPIs. Here’s what they actually look at, with the benchmarks they use:

How to prepare a physical therapy practice for sale, in priority order

1. Get the KPI dashboard production-ready. Visits per PT, total productivity %, units per visit, denial rate, no-show rate, visits per episode, payer mix, by clinic, by therapist, monthly, with 24-36 months of history. The aggregators will rebuild this from raw data, so present it cleanly with your normalized EBITDA bridge.
2. Drive productivity to 1.8-2.0 visits/hour and 75-85% utilization. Below those marks signals operational slack; above them risks quality flags. A 12-month productivity improvement project before going to market routinely adds turns to the multiple.
3. Diversify the payer mix. If you’re 60%+ Medicare, that’s a reimbursement-risk discount. Build commercial relationships, add cash-pay services (wellness, performance, sports), reduce single-payer dependency.
4. De-risk referral concentration. No single orthopedic group above 15-20% of revenue. If you can, sign referral relationships into formal arrangements that survive the sale.
5. Document the systems. SOPs by function (intake, eval, treatment, documentation, billing, denials, AR follow-up), the org chart, supervisor depth (DPT clinical leads, regional managers if multi-site). The aggregator’s biggest fear is “does this run without the owner-PT?” – prove it does.
6. Strengthen clinician retention. Put retention agreements on your key 3-5 PTs and clinical leads before listing. Aggregators discount heavily for key-person flight risk.
7. Address the 2026 CMS changes proactively. Documentation standards, threshold tracking, APM participation status, outcome-tracking infrastructure. Value-based payment readiness is the differentiator the platforms are paying for in 2026.
8. Clean the financials. Accrual accounting, normalized owner-PT compensation (separate clinical labor at market rate from owner equity comp), documented add-backs, real estate paid above market to a related party, family salaries. A QoE rebuild routinely strips 10-25% from sloppy presentations.

The dangers and traps: what kills PT practice deals in diligence

• KPIs that fall apart under aggregator scrutiny. Reported productivity at 2.0 visits/hour, but rebuilt from raw scheduling data it’s 1.4. This is the most common PT deal-killer.
• Owner-PT dependency. The owner sees 40% of patients personally and is the rainmaker for new referrals. The aggregator is buying the owner’s body, not a business. Structures as a heavy earn-out tied to 3-5 year personal retention.
• Referral source concentration. 35% of new patients come from one orthopedic group. The aggregator runs a risk model and discounts for the chance the orthopedic group sells, switches, or in-sources.
• Heavy Medicare exposure with no commercial diversification. 70%+ Medicare in a market with declining reimbursement = real multiple compression.
• Documentation problems and denial rate above 10%. Signals operational weakness and audit exposure under 2026 CMS rules.
• Clinician flight risk. Senior PTs with valuable patient relationships and no non-compete. Loss of 1-2 senior PTs during diligence can kill the deal.
• Bespoke or aged EMR. Custom-built systems, paper charts, or unsupported EMR platforms = real integration cost the aggregator prices in.
• Compliance landmines. Cash-pay billing for Medicare-covered services without proper documentation (this is a CMS violation), questionable units-per-visit patterns that look like over-billing, supervision-ratio violations for PTAs.
• EBITDA that doesn’t survive QoE. Owner-PT compensation not normalized (you’re a $200K PT plus $400K owner; the buyer normalizes you to $200K and your EBITDA shrinks by $400K), real estate paid above market to a related party, family on payroll.

Our view on where the PT M&A market is going

Three forces shape the 2026 PT M&A market. One: the platforms (Upstream, Athletico, Confluent, Ivy, ATI) are 90%+ done with their primary platform-formation phase. The buyer universe is concentrated and disciplined. You’re not selling into a frothy market with a dozen first-time entrants – you’re selling to 5-7 well-capitalized operators who price aggressively but rationally. Two: the 2026 CMS changes (separate APM conversion factors, tighter documentation, the ~$2,480 threshold) compress reimbursement for practices not ready for value-based payment, and expand it for those who are. APM-ready practices are worth meaningfully more in 2026 than in 2024. Three: the consolidators are operationally tired and selective. They’re paying premium for clean, productive, diversified practices and discounting heavily for fixer-uppers.

The implication for an owner: preparation is more important now than at any point in the last 5 years. A $1.5M-EBITDA practice with 2.0 visits/hour, 80% productivity, diversified commercial-heavy payer mix, low referral concentration, retention agreements on key PTs, clean WebPT-based systems, and value-based payment infrastructure will trade at 9-11x. The same $1.5M-EBITDA practice with 1.4 visits/hour, 65% Medicare, 35% concentrated referrals, owner-PT dependency, and paper charts will trade at 4-5x and probably structure as 60% earn-out. That’s a $7-9M difference in enterprise value on the same headline EBITDA, controllable over a 12-24 month preparation window. The window is open, but it rewards the prepared.

Related guides: healthcare business valuation, selling a behavioral health practice, selling a home health agency, selling an ABA therapy business, selling a medical billing / RCM company, selling an RIA / wealth management firm, selling a medical device manufacturer, how private equity creates value, which industries PE is buying most, sell your business, the buyer-paid broker alternative, business brokers by state, how to value a small business, about CT Acquisitions, or use our free valuation tool or book a confidential call.

The five pillars of how CT Acquisitions works

Frequently asked questions

How much is my physical therapy practice worth in 2026?

US outpatient physical therapy practices typically sell for 3x to 16x EBITDA, depending heavily on size and operational quality. Small clinics under $5M revenue typically sell for 3x to 6x EBITDA (the 5-year average is roughly 3.6x per WebPT industry data). Mid-size regional groups with $5-50M revenue sell for 5x to 9x EBITDA. Larger platforms with $5M+ EBITDA, diversified payer mix, and real management teams sell for 10x to 13x. Premium platform deals reach the mid-teens (MOTION PT’s sale to Confluent Health in 2023 was reported at ~12.5x EBITDA). The biggest drivers within the range are productivity (1.8-2.2 visits/PT/hour, 75-85% utilization), payer-mix diversification, referral-source concentration, clinician retention, and value-based payment readiness.

Who is buying physical therapy practices in 2026?

The PT consolidator landscape is concentrated. Named buyers include Upstream Rehabilitation (1,200+ clinics, 28 states – the largest dedicated PT company; PE-backed), Athletico (900+ clinics post-Pivot acquisition; BPOC and PE backing), Confluent Health (650+ clinics in 35 states; PE-backed, paid ~12.5x for MOTION PT in 2023; explored a 2024 sale, called off Q1 2025), Ivy Rehab (560+ clinics; TPG and others backing), ATI Physical Therapy (350+ clinics; underwent a 2025 take-private with a new CEO effective April 30, 2025), U.S. Physical Therapy NYSE: USPH (public; ~800+ clinics via partnership model with majority-owned stakes), and Access PT & Wellness (Confluent affiliate, acquired County PT in January 2025). Plus regional consolidators and individual PT-buyers for smaller practices. Zero new platform buyouts were announced in 2024, but tuck-in activity resumed in 2025 – the buyer pool is well-funded but selective.

What are the KPIs aggregators diligence most carefully in a PT practice?

Visits per PT per hour (benchmark 1.8-2.2; world-class >2.0); total productivity percentage (75-85%); units per visit (3.5+ units/visit, 4.4 units/hour daily); payer mix breakdown (commercial vs Medicare vs Medicaid vs workers comp vs cash-pay – diversified is preferred, heavy Medicare exposure compresses the multiple); denial rate (<5-7%, ideally <3%); authorization and Medicare threshold compliance ($2,480 threshold for 2026); no-show / cancellation rate (<10% no-show, <15% combined); average visits per episode (10-14 for orthopedic referrals); PT and PTA workforce structure (supervision ratios, turnover, retention); referral source diversification (no single referrer above 15-20%); EMR and billing stack (WebPT/Net Health/Raintree preferred over bespoke); and value-based payment / APM readiness (a 2026 differentiator). Aggregators will rebuild all of these from your raw scheduling and billing data, so the numbers have to hold up under reconstruction.

How does productivity (visits per hour) affect my PT practice’s value?

Productivity is the headline labor-economics metric and a direct multiple driver. The benchmark is 1.8-2.2 visits per PT per hour, with total productivity (clinical billable time as a percentage of scheduled time) at 75-85%. Below 1.5 visits/hour signals operational slack – either too many seats for the patient volume, poor scheduling discipline, or excessive non-clinical time. Above 2.5 visits/hour raises quality concerns and burnout risk. Two practices with the same revenue but different productivity sell at different multiples because the buyer’s post-close margin is fundamentally different – a 1.6 visits/hour practice means the buyer has to either accept lower margin or push productivity up (which risks clinician retention and quality). A 12-month productivity improvement program before listing is one of the highest-ROI preparation moves available.

Why does payer mix matter so much when selling a PT practice?

Because reimbursement profiles diverge sharply by payer, and the aggregator models post-close revenue based on the mix. Medicare reimbursement for PT has been under pressure for years (and the 2026 CMS changes only partially offset it for non-APM participants at ~$33.40/RVU, a ~1.75% average net increase that doesn’t keep pace with cost growth). Commercial reimbursement is higher and more variable but represents the upside. Workers comp pays well but is workflow-heavy and concentrated in injury-prone industries. Cash-pay is the highest margin but requires patient willingness to forgo insurance benefits. The most common ‘premium’ profile cited in PT M&A is roughly 75% commercial / 25% cash-pay with minimal Medicare exposure. A practice that’s 70%+ Medicare with no commercial diversification gets discounted because the aggregator can’t easily price the next 3 years of reimbursement risk.

How do I increase the value of my PT practice before selling?

In priority order: (1) get the KPI dashboard production-ready and push the numbers toward best-in-class – productivity at 1.8-2.0 visits/hour, utilization 75-85%, units per visit ~3.5, denial rate <5%; (2) diversify the payer mix away from heavy Medicare exposure toward commercial and cash-pay; (3) de-risk referral concentration (no single source >15-20%) and ideally formalize the relationships; (4) document systems and reduce owner-PT dependency – install clinical leads, transition relationships, document SOPs; (5) lock in key clinicians with retention agreements before listing; (6) get APM/value-based payment infrastructure in place (the 2026 differentiator); (7) modernize the EMR/billing stack if you’re on paper or bespoke systems; (8) clean the financials and prepare a QoE-ready normalized EBITDA bridge that survives a buyer’s rebuild. Most of these are 12-24 month projects, and the combination can shift a $1.5M-EBITDA practice from 5x to 10x+ – the same business, $7-9M more in enterprise value.

How long does it take to sell a physical therapy practice?

Traditional broker-listed PT practices typically take 9-15 months. Off-market sales to a PE-backed PT platform (Upstream, Athletico, Confluent, Ivy, ATI) or a strategic acquirer typically take 90-180 days, because the buyer is pre-qualified, actively rolling up, and looking specifically for practices in your geography, size range, and KPI profile. PT diligence is well-trodden ground for these acquirers – they reconstruct your productivity and revenue KPIs from raw scheduling data, audit the payer mix and denial rates, do a QoE rebuild on EBITDA, review clinician contracts and non-competes, run referral concentration analysis, and verify compliance (Medicare threshold tracking, supervision ratios, documentation standards). Many PT deals include earn-out structures tied to clinician retention or client volume, particularly for owner-PT-dependent practices, which extend the full payout 24-60 months beyond closing.

Do I need a business broker to sell my PT practice?

For small practices (under $1M EBITDA), a healthcare-focused business broker can work but charges 8-15% commissions. For mid-size and platform-scale PT practices, a buyer-paid sell-side advisor with direct relationships into the major PT platforms (Upstream, Athletico, Confluent, Ivy, ATI), the dedicated healthcare-services PE sponsors (TA Associates, TPG, BPOC, Audax, etc.), and the regional consolidators typically produces better outcomes – higher multiples (often 1-3 turns above a generic marketing process), better-matched buyers (the partnership-model platforms like USPH are very different deals from the full-buyout platforms), faster close, and no seller fee. A properly run competitive process that puts 2-3 platforms in active bidding routinely lifts the price by 15-25% versus a single-buyer negotiation – especially given the platforms know each other and price aggressively when competing.

Related research

• Free Business Valuation Tool, your business is worth in 90 seconds
• The Business Broker Alternative Guide (national pillar)
• Business Brokers by State, with a free alternative
• The Complete Guide to Selling Your Business in 2026
• What’s My Business Worth? Founder’s Valuation Guide
• Who Buys These Companies? Buyer Types Explained
• How to Sell to Private Equity, A Founder’s Walkthrough
• Owner’s Pre-Exit Checklist, 90 Days Before You List
• CT Commentary, Founder & M&A Insights

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch